Neuromuscular

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive team.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending September 4, 2021.

Craig Martin, CEO, Global Genes, offered his inside perspective on the multistakeholder initiative and the fruits it hopes to bear for patients with rare CNS diseases.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 3, 2021.

Advocacy organization Cure SMA provides insight on the importance of continuing to push for standardized newborn screening and how it can positively impact outcomes in SMA.

Investigators found that strength training improved muscle strength, balance, gait speed, and gross motor function in pediatric and adolescent patients.

Investigators concluded that feedback from patients and caregivers should be incorporated as telehealth continues to be integrated into daily clinical care.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending August 28, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 27, 2021.

Investigators found incobotulinumtoxinA treatment decreased unstimulated salivary flow rate and increased GICS ratings in children.

The chief medical officer of Wave Life Sciences outlined the FOCUS-C9 study, which has incorporated feedback from patients with both ALS and FTD, as well as investigators in the research field.

The long-acting C5 complement inhibitor, developed by Alexion and approved for atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria (PNH), failed to show an effect on ALSFRS-R score.

The potential of a new investigational treatment for C9orf72-associated amyotrophic lateral sclerosis and frontotemporal could offer long-lasting effects for patients.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 20, 2021.

The chief medical officer of Wave Life Sciences spoke on the FOCUS-C9 study and the potential of WVE-004 to generate positive outcomes for patients.

The potential of a new investigational treatment, WVE-004, was discussed by the chief medical officer of Wave Life Sciences, the company that developed the molecule for C9-ALS and C9-FTD.

Program chairs Fred D. Lublin, MD, and Stephen Silberstein, MD, offer insight into the third annual IFN meeting, which is set for September 17-18, 2021, to be held in a virtual setting.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending August 14, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 13, 2021.

The chief medical officer of Wave Life Sciences, Michael Panzara, MD, MPH, discussed the potential of an investigational new treatment, WVE-004, for patients with C9orf72-associated ALS and FTD.

Michael Panzara, MD, MPH, chief medical officer of Wave Life Sciences, spoke on the FOCUS-C9 study, which recently began dosing of an investigational treatment, WVE-004, for patients with ALS and FTD.

The autologous, expanded Treg cell therapy was found safe and tolerable in a phase 1 study of 3 patients with ALS.

Following the commencement of a study exploring WVE-004, an investigational treatment for C9-ALS and C9-FTD, the director of the Sean M. Healey & AMG Center for ALS discussed the clinical implications and the treatment’s potential.

Two unblinded interim analyses by the Data Monitoring Committee are planned to assess the futility of reldesemtiv, with the first occurring 12 weeks after one-third of the sample size is randomized.

The director of the Sean M. Healey & AMG Center for ALS outlined the trial, which will evaluate ideal dose level and frequency of the investigational treatment for patients with C9-ALS and C9-FTD.

Investigators obtained a molecular diagnostic yield of 39% in 66 sequential, unselected individuals with diverse presentations of rare neurogenetic disorders when using a model that integrates additional assays.